As major pharmacy chains like Walgreens continue to close hundreds of stores nationwide, pharmacy deserts are increasing ...

Type of data available on UK Pharmascan registration, with a breakdown on whether the live record is for a new indication, ...

Nuvation Bio is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment ...

The companies have said they will create customised AI models and agents that Novo Nordisk can use for early research and ...

At ASCO 2025, ImmunityBio’s chief medical officer, Dr Sandeep Reddy, spoke with pharmaphorum about the importance of FDA Expanded Access authorisation for its Cancer BioShield platform, anchored by ...

9 June 2025: The PM (Pharmaceutical Marketing) Society is delighted to announce a new partnership with the CIM (Chartered Institute of Marketing) to build capability and excellence in marketing in the ...

BioNTech has agreed to buy another specialist in mRNA-based vaccines and therapeutics, fellow German biotech CureVac, in an all-stock deal valued at around $1.25 billion.

While Takeda's Qdenga (TAK-003) shot is approved as a two-dose regimen to protect people from the disease in dozens of countries around the world, the drugmaker withdrew its FDA filing in mid-2023 ...

The pressure to execute a flawless drug or therapy launch has never been greater and continues to lay the foundation for long ...

If that sounds like the storyline to Marvel's latest superhero tale, that's because it is. The publisher's latest custom ...

SpliceBio's lead in-house pipeline project is in Stargardt disease, an IRD with no approved therapies that is caused by ...

The rate for the latter half of the year brings the full-year average to 23.4% – rising to 24.3% next year and 26% in 2027 – ...